Cargando…

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?

There are few randomized trials to evaluate the use of PSMA-PET in the planning of post-prostatectomy radiotherapy. There are two unresolved questions 1) should we increase the dose to lesions visible on PSMA-PET 2) can we reduce dose in the case of a negative PSMA-PET. In this review, we summarize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Champion, Ambroise, Zwhalen, Daniel Rudolf, Oehler, Christoph, Taussky, Daniel, Kroeze, Stephanie G. C., Burger, Irene A., Benzaquen, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548198/ https://www.ncbi.nlm.nih.gov/pubmed/37799463 http://dx.doi.org/10.3389/fonc.2023.1268309

Ejemplares similares

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2018)

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

A Literature Review of Racial Disparities in Prostate Cancer Research
por: Vermeille, Matthieu, et al.
Publicado: (2023)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

(68)Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
por: Yuminaga, Yuigi, et al.
Publicado: (2021)

Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates
por: Rosenzweig, Barak, et al.
Publicado: (2022)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy
por: Bashir, Usman, et al.
Publicado: (2019)

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
por: Zhou, Xing, et al.
Publicado: (2021)

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?
por: Laudicella, Riccardo, et al.
Publicado: (2023)

Improved oncological outcome after radical prostatectomy in patients staged with (68)Ga-PSMA-11 PET: a single-center retrospective cohort comparison
por: Ferraro, Daniela A., et al.
Publicado: (2020)

All that Glitters on PSMA is Not a Lesion: An Unusual Artifact on PSMA PET/CT
por: Dev, Indraja D., et al.
Publicado: (2021)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Pelvic salvage (SBRT) radiotherapy based on (68)Ga-PSMA PET/CT: About a case
por: Slaoui, A., et al.
Publicado: (2019)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Ga-68-PSMA PET/CT ? or PET/MRI ?, Mp-MRI ? in diagnosis and radiotherapy planning in a patient with prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2020)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Changes of Radiation Treatment Concept Based on (68)Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
por: Bottke, Dirk, et al.
Publicado: (2021)

False Positive Findings of [(18)F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels
por: Orevi, Marina, et al.
Publicado: (2022)

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
por: Zschaeck, Sebastian, et al.
Publicado: (2018)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer
por: Ben Shimol, Jennifer, et al.
Publicado: (2022)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

(68)Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
por: Tan, Janice S.H., et al.
Publicado: (2019)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bv3q1j3r8fcu7va3unka233itv